|
|
Volumn 12, Issue 10, 2013, Pages 730-
|
|
Deal watch: AstraZeneca bets on FibroGen's anaemia drug
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
ENZYME INHIBITOR;
FG 4592;
HYPOXIA INDUCIBLE FACTOR;
HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR;
IRON;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
UNCLASSIFIED DRUG;
ALTITUDE;
ANEMIA;
CHINA;
CHRONIC KIDNEY DISEASE;
DRUG APPROVAL;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SELECTIVITY;
ERYTHROPOIESIS;
HUMAN;
NOTE;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
UNITED STATES;
ANEMIA;
CLINICAL TRIALS, PHASE III AS TOPIC;
COOPERATIVE BEHAVIOR;
DRUG DESIGN;
DRUG INDUSTRY;
ENZYME INHIBITORS;
GLYCINE;
HUMANS;
ISOQUINOLINES;
PROCOLLAGEN-PROLINE DIOXYGENASE;
RENAL INSUFFICIENCY, CHRONIC;
|
|
EID: 84885005460
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4135 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
